Megace

Megestrol Acetate, the active ingredient in Megace, is a progestin presented as an oral tablet for systemic use. It is employed to stimulate appetite in cachexia associated with AIDS or cancer and as an antineoplastic agent in advanced breast and endometrial cancer. GNH USA supplies Megace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Megace is a synthetic progestin used in oncology and supportive care to address specific disease processes. - Cachexia associated with AIDS or cancer: improves appetite and promotes weight gain. - Advanced breast cancer: provides antineoplastic activity to help control tumor progression. - Endometrial cancer: used as hormonal therapy to inhibit disease growth.

Megace may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Edema or fluid retention - Increased blood glucose levels - Fatigue or weakness - Hormonal changes such as menstrual irregularities - Gastrointestinal discomfort

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Severe adrenal suppression - Hepatotoxicity with elevated liver enzymes - Unexplained weight gain due to fluid overload

Megace requires careful monitoring and specific safety measures. - Pregnancy: Avoid use; potential risk to fetus is unknown. - Breastfeeding: Not recommended; drug may pass into milk. - Diabetes: Monitor blood glucose closely as hyperglycemia can worsen. - Thrombotic risk: Assess patient history for clotting disorders before initiation. - Liver function: Conduct baseline and periodic liver enzyme tests. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Megace can alter the activity of several concomitant medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Antidiabetic agents: may exacerbate hypoglycemia or hyperglycemia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise megace plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Hormonal contraceptives: reduced efficacy due to progestogenic activity.